Does Incorporation of EPA and DHA in Lipoproteins Differ According to Apolipoprotein E Genotype?
|ClinicalTrials.gov Identifier: NCT01544855|
Recruitment Status : Completed
First Posted : March 6, 2012
Last Update Posted : March 3, 2014
|Condition or disease||Intervention/treatment||Phase|
|Healthy||Dietary Supplement: omega-3 fatty acids||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||80 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||Does Incorporation of EPA and DHA in Lipoproteins Differ According to Apolipoprotein E Genotype?|
|Study Start Date :||February 2011|
|Actual Primary Completion Date :||May 2012|
|Actual Study Completion Date :||May 2012|
Experimental: APOE4 carriers
The results obtained for APOE4 carriers will be compared to the one obtained from APOE4 non-carriers. Carriers are defined as being at least carrier of one APOE4 allele.
Dietary Supplement: omega-3 fatty acids
Participants will take 700 mg/d of EPA and 500 mg/d of DHA as ethyl esters for one month (Ocean Nutrition, Dartmouth, NS) which is about 10 times the current estimated intake of young adults (21). This corresponds to one capsule with breakfast and one capsule with diner.
- Distribution of EPA and DHA in lipoproteins by APOE genotype [ Time Frame: Once each week for 28 days ]We will measure % and concentration of EPA and DHA in VLDL, HDL and LDL to evaluate how these fatty acids are transported in the blood and whether APOE genotype changes the distribution of these fatty acids.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01544855
|Centre de recherche sur le vieillissement|
|Sherbrooke, Quebec, Canada, J1H4C4|